Диссертация (1140904), страница 19
Текст из файла (страница 19)
Mathurin P. Trends in the management and burden of alcoholic liver disease/Mathurin P., Bataller R. // Journal of Hepatology. – 2015. Vol. 62 – p. 38–46.56. Mato JM. Role of S-adenosyl-L-methionine in liver health and injury/ Mato JM,Lu SC // Hepatology. – 2007. – Vol.45 (5) . – p. 1306–1312.57. Mato JM. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized,placebocontrolled, double-blind, multicenter clinical trial / Mato JM, Camara J,Fernandez de Paz J et al.
// J Hepatol 1999 – Vol.30(6). – p.1081-1089.58. Mato JM. S-adenosylmethionine: a control switch that regulates liver function/Mato JM, Corrales FJ, Lu SC, Avila MA. // FASEB J. – 2002. – Vol.16 (1) . –p.15–26.59. Moore KP. The management of ascites in cirrhosis: report on the consensusconference of the International Ascites Club/ Moore KP, Wong F, Ginиs P, et al. //Hepatology. – 2003. – Vol.38. – p. 258–266.60. Moreau R. G-CSF Therapy for Severe Alcoholic Hepatitis: Targeting LiverRegeneration or Neutrophil Function? / Moreau R., Rautou P.
// Am JGastroenterol. – 2014. – Vol. 109. – p. 1424-1426.12161. Naveau S. A double-blind randomized controlled trial of infliximab associatedwith prednisolone in acute alcoholic hepatitis/ Naveau S, Chollet-Martin S,Dharancy S et al. // Hepatology. 2004; 39:1390-762. Nguyen-Khac E. Glucocorticoids plus N-Acetylcysteine in Severe AlcoholicHepatitis / E.
Nguyen-Khac, T. Thevenot, M. Piquet // New England Journal ofMedicine. – 2011. – Vol. 365. – p.1781-1789.63. O’Shea RS. Alcoholic liver disease / O’Shea RS, Dasarathy S, McCullough AJ,et al. //Hepatology. – 2010. – Vol. 51. – p. 307–328.64. Ou X. Inhibition of human betaine-homocysteine methyltransferase expression byS-adenosylmethionineand methylthioadenosine / Ou X, Yang H, Ramani K, AraAI, et al.
// Biochem J. – 2007. – Vol. 401 (1). – p. 87–96.65. Pavlov C. Transient elastography for diagnosis of stages of hepatic fibrosis andcirrhosis in people with alcoholic liver disease (Review) / Pavlov CS, Casazza G,Nikolova D // The Cochrane Library – 2015 – Vol 1.66. Petrasek J.
Toll-like receptors in the pathogenesis of alcoholic liver disease /Petrasek J, Mandrekar P, Szabo G. // Gastroenterol Res Pract. – Adv Clin Chem. –2013. – Vol. 59 – p. 155-20167. Pittas AG.. Insulin therapy and in hospital mortality in critically ill patients:systematic review and meta-analysis of randomized controlled trials/ Pittas AG,Siegel RD, Lau D. // JPEN. – 2006. – Vol. 30 (22) . – p. 164-72.68. Posey D. The estimation of blood alcohol concentration: Widmark revisited /Posey D, Mozayani A. // Forensic Sci Med Pathol. – 2007. – Vol. 3(1) . – p.33-9.69. Rehm J.
Alcohol as a risk factor for liver cirrhosis: A systematic review andmeta- analysis/ Jurgen Rehm, Benjamin Taylor, Satya Mohapatra et al. // Drug andAlcohol Review. – 2010. – Vol.29. – p. 437-445.70. Rehm J. Global burden of alcoholic liver diseases / Jurgen Rehm, Andriy V.Samokhvalov, Kevin D. Shield // Journal of Hepatology.
– 2013. – Vol. 59. –p.160–168.12271. Rey JW. Pro12Ala polymorphism of the peroxisome proliferator-activatedreceptor g2 in patients with fatty liver diseases / Rey JW, Noetel A, Hardt A, et al.// World J Gastroenterol. – 2010. – Vol.16. – p. 5830-7.72. Singh V. Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis:A Randomized Pilot Study / Singh V., Sharma A., Narasimhan R. // Am JGastroenterol. – 2014.
– Vol. 109. – p. 1417–1423.73. Song Z. S-adenosylmethionine(SAMe) protects against acute alcohol inducedhepatotoxicity in mice/ Song Z, Zhou Z, Chen T, et al. // J Nutr Biochem. – 2003.– Vol.14 (10). – p. 591–597.74. Spengler E. Alcoholic Hepatitis: Current Management / Spengler E., DunkelbergJ., Schey R. // Digestive Diseases and Sciences. – 2014. Vol.
59. (10) – p. 23572366.75. Tilg H, Day CP. Management strategies in alcoholic liver disease/ Tilg H, DayCP. // Nat Clin Pract Gastroenterol Hepatol. – 2007. – Vol. 4. – p. 24-34.76. Tilg H. Cytokines in alcoholic and nonalcoholic steatohepatitis / Tilg H, DiehlAM. // N Engl J Med.
– 2000. – Vol. 343. – p. 1467–1476.77. Torres L. Liver-specific methionine adenosyltransferase MAT1A gene expressionis associated with a specific pattern of promoter methylation and histoneacetylation: implications for MAT1A silencing during transformation / Torres L,Avila MA, Carretero MV, et al. // FASEB J.
– 2000. – Vol.14 (1). – p. 95–102.78. Trespi E. TUDCA, UDCA and ademethionine in the treatment of alcohol-inducedliver damage / Trespi E, Vigoni R, Matti C, Colla C. // J Hepatol. – 1997. – Vol.26. – p. 12879. Wechsler H. Binge drinking: the five/four measure / Wechsler H, Austin SB. // JStud Alcohol. – 1998. – Vol. 59. – p.122-124.80. WHO Global status report on alcohol and health / editors Vladimir Poznyak andDag Rekve // 2014. – 378 p.81. Yin M. Reduced early alcohol-induced liver injury in CD14-deficient mice / YinM, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, et al. // J Immunol.– 2001. – Vol.
166. – p. 4737-4742.12382.Bernadt MW. Comparison of questionnaire and laboratory tests in the detection ofexcessive drinking and alcoholism / Bernadt MW, Mumford J, Taylor C. et. al. //Lancet – 1982 – Vol 1 p. 325–328..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
